Streetbeat News

Regulatory

SABS

SAB Biotherapeutics (NASDAQ:SABS) will present its novel immunotherapy platform and positive clinical data for SAB-176, a fully-human polyclonal antibody therapeutic for influenza treatment, at the BIO 2023 International Convention. The company will also discuss recent Breakthrough Therapy and Fast Track Designations granted by the FDA and explore out-licensing and partnering opportunities for SAB-176 and SAB-185 programs.

Portfolio Pulse from Happy Mohamed

May 30, 2023 | 12:37 pm

CEI

Camber Energy's majority-owned subsidiary, Viking Energy Group, announced that its subsidiary, Viking Protection Systems, received a Notice of Allowance from the USPTO for a patent application related to its transmission line ground fault prevention system. The technology aims to improve the resiliency and reliability of existing electric infrastructure.

Portfolio Pulse from Happy Mohamed

May 30, 2023 | 12:36 pm

PYXS

Pyxis Oncology has announced the dosing of the first subject in the Phase 1 trial of PYX-106, a novel cancer immunotherapy. This marks a significant milestone for the company as it advances its clinical development program.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2023 | 12:35 pm

NTRA

Natera announced that new data will be presented at the 2023 ASCO Meeting in 13 studies across multiple cancer types, including oral presentations in Sarcoma and CRC, immunotherapy monitoring data from the Phase 3 EMPOWER-Lung 1 study, and updates from the CIRCULATE-Japan study in CRC.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2023 | 12:32 pm

AAPL

Apple Inc (NASDAQ:AAPL) is seeking a concrete reason or legal requirement to comply with the Indian government's directive to remove betting apps from its App Store. Apple has removed some apps banned by the IT ministry in February, while working on a suitable solution for others.

Portfolio Pulse from Shomik Sen Bhattacharjee

May 30, 2023 | 12:23 pm

SSKN

STRATA Skin Sciences (NASDAQ:SSKN) has announced the treatment of the first six patients in the TheraClearX clinical study for acne. The study aims to evaluate the efficacy and safety of TheraClearX as a stand-alone treatment for mild to moderate acne in 30 healthy subjects aged 12-40.

Portfolio Pulse from Happy Mohamed

May 30, 2023 | 12:16 pm

PBA

Pembina Pipeline Corporation (NYSE:PBA) has signed a Memorandum of Agreement with Marubeni Corporation to develop a low-carbon ammonia supply chain from Western Canada to Japan and other Asian markets. The project includes the joint development of a low-carbon hydrogen and ammonia production facility in Alberta, Canada.

Portfolio Pulse from Happy Mohamed

May 30, 2023 | 12:12 pm

RETO

ReTo Eco-Solutions (NASDAQ:RETO) has regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2), as confirmed by a notification letter from Nasdaq on May 26, 2023.

Portfolio Pulse from Happy Mohamed

May 30, 2023 | 12:11 pm

ESTA

Establishment Labs Holdings Inc. (NASDAQ:ESTA) has received CE marking under the European Medical Device Regulation for its Motiva Injector, Motiva Inflatable Balloon, and Motiva Channel Dissector. The approval marks an important step in the evolution of plastic surgery and expands the market for minimally invasive aesthetic procedures.

Portfolio Pulse from Happy Mohamed

May 30, 2023 | 12:10 pm

MRNA

Moderna announced that two abstracts on mRNA-4157 (V940), an investigational mRNA individualized neoantigen therapy, will be presented at the 2023 ASCO Annual Meeting in Chicago.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2023 | 12:09 pm